StreetInsider.com News Articles

Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026

Mon, 01 Jun 2026 16:15:00 -0400

DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.

To access the live webcast, please use the

Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026

Mon, 01 Jun 2026 16:15:00 -0400

To access the live webcast, please use the

Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Mon, 18 May 2026 16:05:00 -0400

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Company Webcast

The webcast presentation will take place at 9:15 a.m. Eastern time on Thursday, May 28, 2026. The webcast can be accessed by visiting the

Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Mon, 18 May 2026 16:05:00 -0400

Company Webcast

The webcast presentation will take place at 9:15 a.m. Eastern time on Thursday, May 28, 2026. The webcast can be accessed by visiting the

Aytu BioScience (AYTU) Misses Q3 EPS by 53c

Wed, 13 May 2026 16:43:22 -0400

Aytu BioScience (NASDAQ: AYTU) reported Q3 EPS of ($0.53). Revenue for the quarter came in at $12.4 million.

For earnings history and earnings-related data on Aytu BioScience (AYTU) click here.

Form 10-Q AYTU BIOPHARMA, INC For: Mar 31

Wed, 13 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260513/26485998.html

Form 10-Q AYTU BIOPHARMA, INC For: Mar 31

Wed, 13 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260513/26485998.html

Form 8-K AYTU BIOPHARMA, INC For: May 13

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485908.html

Form 8-K AYTU BIOPHARMA, INC For: May 13

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485908.html

Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results

Wed, 13 May 2026 16:05:00 -0400

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates

Total net revenue of $12.4 million

Adjusted EBITDA¹ of $(2.8) million, which includes EXXUA™ (gepirone) extended-release tablets ("EXXUA") launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ("MDD") market

$26.7 million cash balance at March 31, 2026

Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time

DENVER, CO / ACCESS Newswire / May 13, 2026

Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results

Wed, 13 May 2026 16:05:00 -0400

EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates
Total net revenue of $12.4 million
Adjusted EBITDA¹ of $(2.8) million, which includes EXXUA™ (gepirone) extended-release tablets ("EXXUA") launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ("MDD") market
$26.7 million cash balance at March 31, 2026
Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time

DENVER, CO / ACCESS Newswire / May 13, 2026

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

Wed, 06 May 2026 16:05:00 -0400

DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

Wed, 06 May 2026 16:05:00 -0400

DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question

Form 8-K AYTU BIOPHARMA, INC For: Mar 31

Thu, 02 Apr 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260402/26266708.html

Form 8-K AYTU BIOPHARMA, INC For: Mar 31

Thu, 02 Apr 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260402/26266708.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: LYTTON LAURENCE W

Tue, 17 Feb 2026 13:32:00 -0400
si-local-file:///var/storage/secattach/20260217/26010708.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: LYTTON LAURENCE W

Tue, 17 Feb 2026 13:32:00 -0400
si-local-file:///var/storage/secattach/20260217/26010708.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: AWM Investment Company, Inc.

Fri, 13 Feb 2026 14:36:00 -0400
si-local-file:///var/storage/secattach/20260213/25998900.html

Form SCHEDULE 13G/A AYTU BIOPHARMA, INC Filed by: AWM Investment Company, Inc.

Fri, 13 Feb 2026 14:36:00 -0400
si-local-file:///var/storage/secattach/20260213/25998900.html

Aytu BioScience (AYTU) Misses Q2 EPS by 105c

Tue, 03 Feb 2026 16:27:46 -0400

Aytu BioScience (NASDAQ: AYTU) reported Q2 EPS of ($1.05), $1.05 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $15.2 million.
For earnings history and earnings-related data on Aytu BioScience (AYTU) click here.

Form 10-Q AYTU BIOPHARMA, INC For: Dec 31

Tue, 03 Feb 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260203/25938726.html

Form 10-Q AYTU BIOPHARMA, INC For: Dec 31

Tue, 03 Feb 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260203/25938726.html

Form 8-K AYTU BIOPHARMA, INC For: Feb 03

Tue, 03 Feb 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260203/25938625.html

Form 8-K AYTU BIOPHARMA, INC For: Feb 03

Tue, 03 Feb 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260203/25938625.html

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Tue, 03 Feb 2026 16:05:00 -0400

Total net revenue of $15.2 million
Adjusted EBITDA¹ of $(0.8) million, which includes EXXUA launch investments
$30.0 million cash balance at December 31, 2025
Company launched EXXUA^™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market
Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time
DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative